

Request title:
Migraine and drug usage

Reference Number: F4486
Date of Response: 22nd April 2022.

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

**Request and Royal Devon and Exeter NHS Foundation Trust
Response**

I have a freedom of information request.

1, .How many patients have been treated with the following drugs in the past 4 months:

- Enuma (Aimovig) - any disease **6**
- Fremanezumab (Ajovy) - any disease **67**
- Daclizumab (Emgality) - any disease **7**
- Botulinum Toxin (i.e., Botox, Dysport, Yeoman) - migraine ONLY.
Approximately 100 (manual count from clinic schedules during this period).

Please note, the Trust Pharmacy have used the 4 months November 2021 to February 2022.

They have calculated how many patients have been treated, by counting all patients who had a prescription processed through pharmacy during this period. They are unable do this for botulinum toxin, as pharmacy do not dispense at patient level. Stock vials are sent to the clinic.

2, .I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Agony, Aimovig, Megalith) for migraine. Could you please answer the following questions:

- Does the trust commission/fund Botulinum Toxin treatment for migraine (Y/N)? **Yes – commissioned by CCG**
- Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)? **Yes – commissioned by CCG**
- In case the trust actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

Not applicable.

- In case the trust actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.

Not applicable.